MedTrace Logo

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT06610201 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

Conditions

  • Von Willebrand Disease (VWD)
  • Von Willebrand Disease (VWD), Type 1
  • Von Willebrand Disease (VWD), Type 2
  • Von Willebrand Disease (VWD), Type 3
  • Von Willebrand Disease, Type 2A
  • Von Willebrand Disease, Type 2M
  • Von Willebrand Disease, Type 2N

Interventions

OTHER

Clinical outcomes of patients with VWD, Type 1

Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1

OTHER

Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3

Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.

Sponsors & Collaborators

  • Hemab ApS

    lead INDUSTRY

Principal Investigators

  • VP of Clinical Research · Hemab ApS

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States
  • Australia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06610201 on ClinicalTrials.gov